Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-resistant Epithelial Ovarian Cancer”

229 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 229 results

Large-scale testing (Phase 3)Study completedNCT00262990
What this trial is testing

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Novartis Pharmaceuticals 829
Testing effectiveness (Phase 2)UnknownNCT01100372
What this trial is testing

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Medical University Innsbruck 154
Early research (Phase 1)Study completedNCT00003588
What this trial is testing

Gene Therapy in Treating Patients With Ovarian Cancer

Who this might be right for
Ovarian Cancer
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT06646627
What this trial is testing

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

Who this might be right for
Ovarian Cancer
Stanford University 48
Early research (Phase 1)Looking for participantsNCT06687070
What this trial is testing

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

Who this might be right for
Platinum-resistant Recurrent Ovarian CancerAdvanced Solid Tumor
Ascentage Pharma Group Inc. 90
Testing effectiveness (Phase 2)Study completedNCT00436644
What this trial is testing

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Who this might be right for
Ovarian CancerPeritoneal Cavity Cancer
Mayo Clinic 18
Early research (Phase 1)Study completedNCT02028117
What this trial is testing

Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients

Who this might be right for
Recurrent Platinum Resistant Ovarian Cancer
Akamis Bio 38
Testing effectiveness (Phase 2)UnknownNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Testing effectiveness (Phase 2)Ended earlyNCT00055432
What this trial is testing

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Who this might be right for
Ovarian CancerPeritoneal Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Ended earlyNCT00023907
What this trial is testing

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Large-scale testing (Phase 3)Study completedNCT00382811
What this trial is testing

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal NeoplasmsOvarian Cancer
MEI Pharma, Inc. 142
Testing effectiveness (Phase 2)Study completedNCT03206047
What this trial is testing

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Study completedNCT03026062
What this trial is testing

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 100
Testing effectiveness (Phase 2)Ended earlyNCT02107378
What this trial is testing

Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma

Who this might be right for
Epithelial Ovarian Carcinoma
SOTIO a.s. 22
Large-scale testing (Phase 3)Study completedNCT01684878
What this trial is testing

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Who this might be right for
Ovarian Cancer
Hoffmann-La Roche 208
Not applicableUnknownNCT05776355
What this trial is testing

NKG2D CAR-NK & Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hangzhou Cheetah Cell Therapeutics Co., Ltd 18
Testing effectiveness (Phase 2)UnknownNCT03467178
What this trial is testing

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Who this might be right for
Recurrent, Platinum-resistant Ovarian Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 119
Early research (Phase 1)Ended earlyNCT03861403
What this trial is testing

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer+2 more
Leap Therapeutics, Inc. 10
Testing effectiveness (Phase 2)Study completedNCT00477386
What this trial is testing

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Indiana University 28
Testing effectiveness (Phase 2)Study completedNCT02759588
What this trial is testing

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CarcinomatosisFallopian Tube Cancer
Genelux Corporation 46
Next Page